In this episode of Denatured, you'll be hearing from Daniel Gil, CEO of Pelage Pharmaceuticals and Francisco Ramírez-Valle, senior vice president of immunology discovery at Eli Lilly. We dive into the long-overlooked hair loss space, exploring why true innovation has lagged, how a regenerative approach aims to reactivate dormant follicles and what early proof-of-concept means for patients.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsDaniel Gil, CEO, Pelage PharmaceuticalsFrancisco Ramírez-Valle, Senior Vice President, Immunology Discovery, Eli LillyDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from BioSpace
ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck
France’s biotech ecosystem: science, capital and scale
Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds
Inside Germany’s biotech capital infrastructure and innovation engine
Get summaries like this every morning.
Free AI-powered recaps of BioSpace and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.